The Hemovascular Research Axis is composed of investigators in cardiovascular and blood diseases. This axis is led by Dr. Ernesto Schiffrin, who is also the Physician-in-Chief of the Jewish General Hospital. Dr. Schiffrin is the recipient of a Tier 1 Canada Research Chair, directs the Hypertension and Vascular Research Unit of the LDI and the Cardiovascular Prevention Center of the Hospital, and is an expert in the field of hypertension and vascular disease. Work in Dr. Schiffrin’s laboratory addresses the role of angiotensin, aldosterone, endothelin, immunity and gene regulation by microRNAs in vascular remodeling in hypertension, diabetes and chronic kidney disease. Dr. Schiffrin is President of the International Society of Hypertension and Associate Editor of Hypertension, the journal of the American Heart Association.
Other members of the Hemovascular axis include Dr. David Langleben, a cardiologist expert in pulmonary hypertension who carries out cutting-edge research on endothelin and endothelin antagonists, and the use of genetically engineered human stem cells to treat this disease. Dr. Lorraine Chalifour performs research on gender differences, and the consequences of gestational modulation of estrogens, testosterone and endocrine disruptors molecularly and physiologically in the adult progeny. Also part of the axis is Dr. Stéphanie Lehoux, recipient of a Tier 2 Canada Research Chair, who is an authority in the field of vascular mechanotransduction, investigating the relationship between shear stress, inflammation, and atherosclerosis. Dr. Prem Ponka is internationally renowned in the field of oxidative stress in relation to iron metabolism and anemia, together with Dr. Kostas Pantopoulos. Dr. Mark Blostein researches the role of a novel gamma-carboxylated protein, gas 6, in endothelial cell biology. Collaborations exist with other LDI investigators such as Dr. Koren Mann, who explores the role of arsenic in accelerating atherosclerosis. The research of all these investigators is supported by major funding agencies, including the CIHR, and/or the pharmaceutical industry. Dr. Elizabeth Jones is applying principles of fluid dynamics to the study of the vascular system.
The lab bench research activities of the hemovascular group extend to the clinical arena, with investigations that are carried out at the Jewish General Hospital addressing coronary heart disease and heart failure, hypertension and vascular disease, atherosclerosis, and pulmonary hypertension. These studies cut across numerous disciplines, and involve molecular biology and gene regulation, understanding of host factors, innate and adaptive immunity, epidemiology, and drug development. The program is state-of-the-art and stands out as an example of lab-bench to bedside translation and success.
The hemovascular group publishes actively in the scientific literature. At least 30 or more publications per year originate from the labs of the Hemovascular axis at the Lady Davis Institute, many in the top-ranking journals of the field.
Members of the Hemovascular Research Axis:
Dr. Mark Blostein, Associate Professor of Medicine, McGill University, Hematologist and Director of the Coagulation Laboratories, JGH.
Dr. Elizabeth Jones, Assistant Professor, Department of Chemical Engineering, McGill University, and investigator, LDI.
Dr. David Langleben, Associate Professor of Medicine, McGill University, cardiologist, JGH.
Dr. Stéphanie Lehoux, Canada Research Chair in Cardiovascular Physiology, Assistant Professor of Medicine, McGill University, and Research Scientist, LDI.
Dr. Kostas Pantopoulos, Professor of Medicine, McGill University, Research Scientist LDI.
Dr. Prem Ponka, Professor of Physiology and Medicine, McGill University, Associate researcher, Hematology, JGH, and Research Scientist LDI.
Dr. Ernesto L. Schiffrin, Professor and Vice-Chair (Research), McGill University, Physician-in-Chief, JGH, Canada Research Chair in Hypertension and Vascular Research, and Director of the Cardiovascular Prevention Centre.